nach oben

Endocrine

Erschienen in:

27.01.2022 | Meta-Analysis

A meta-analysis of combination therapy with gonadotrophin-releasing hormone agonist and growth hormone for children with idiopathic short stature and normal timed puberty

verfasst von: Bo Zhou, Shufang Liu, Jianhong Wang, Ting Zhang, Yuan Yuan, Wenquan Niu, Zhixin Zhang, Lin Wang

Erschienen in: Endocrine | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this meta-analysis is to evaluate whether the combination therapy with gonadotrophin-releasing hormone agonist (GnRHa) and recombinant human growth hormone (rhGH) are effective in the treatment of children with idiopathic short stature (ISS) and normal timed puberty by interrogating data from clinical controlled trials.

Methods

Literature retrieval, trail selection, data abstraction and quality assessment were completed independently by two authors. STATA software (version 14.1) was used for data analyses.

Results

This meta-analysis was conducted based on 8 (4 randomized and 4 non-randomized) controlled trials. A total of 245 ISS children with normal timed puberty were financially analyzed. Overall, combination therapy with GnRHa and rhGH can slightly increase final height by 3.70 and 3.43 cm compared with GH treatment alone and no treatment, final height standard deviation score (FHSDS) by 0.10 and 0.22, final height minus predicted adult height (FH-PAH) by 1.5 and 5.32 cm, final height minus predicted adult height (FH-TH) by 7.70 and 4.32 cm, respectively. Subgroup and meta-regression analyses revealed that study type, sample size, GnRHa duration, and percentage of boys were potential sources of between-trial heterogeneity. There was a low probability of publication bias for above comparisons, as indicated by Egger’s tests.

Conclusions

Our meta-analytical findings indicate that the combination therapy with GnRHa and rhGH can slightly increase the final height of ISS children with normal timed puberty, and the effect was not more obvious than GH alone. We do not recommend the combination therapy as a routine treatment for ISS.

Trial registration number

CRD42019133438

Nur mit Berechtigung zugänglich

S. Jafari-Adli, M. Qorbani, R. Heshmat, S.H. Ranjbar, E. Taheri, M.E. Motlagh, M. Noorozi, O. Safari, G. Shafiee, F. Rezaei, S. Safiri, R. Kelishadi, Association of short stature with life satisfaction and self-rated health in children and adolescents: the CASPIAN-IV study. J. Pediatr. Endocrinol. Metab. 29(11), 1299–1306 (2016). https://doi.org/10.1515/jpem-2016-0215CrossRefPubMed

P. Cohen, A.D. Rogol, C.L. Deal, P. Saenger, E.O. Reiter, J.L. Ross, S.D. Chernausek, M.O. Savage, J.M. Wit, I.S.S.C.W. participants, Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J. Clin. Endocrinol. Metab. 93(11), 4210–4217 (2008). https://doi.org/10.1210/jc.2008-0509CrossRefPubMed

J.M. Wit, P.E. Clayton, A.D. Rogol, M.O. Savage, P.H. Saenger, P. Cohen, Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Horm. IGF Res 18(2), 89–110 (2008). https://doi.org/10.1016/j.ghir.2007.11.004CrossRefPubMed

A. Deodati, S. Cianfarani, Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review. BMJ 342, c7157 (2011). https://doi.org/10.1136/bmj.c7157CrossRefPubMed

A.M. Ramos-Levi, M. Marazuela, Treatment of adult growth hormone deficiency with human recombinant growth hormone: an update on current evidence and critical review of advantages and pitfalls. Endocrine 60(2), 203–218 (2018). https://doi.org/10.1007/s12020-017-1492-1CrossRefPubMed

E. Inzaghi, E. Reiter, S. Cianfarani, The challenge of defining and investigating the causes of idiopathic short stature and finding an effective therapy. Horm. Res. Paediatr. 92(2), 71–83 (2019). https://doi.org/10.1159/000502901CrossRefPubMed

A. Deodati, E. Peschiaroli, S. Cianfarani, Review of growth hormone randomized controlled trials in children with idiopathic short stature. Horm. Res. Paediatr. 76(Suppl 3), 40–42 (2011). https://doi.org/10.1159/000330157CrossRefPubMed

J. Bryant, L. Baxter, C.B. Cave, R. Milne, Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst. Rev. 3, CD004440 (2007). https://doi.org/10.1002/14651858.CD004440.pub2CrossRef

J.F. Sotos, N.J. Tokar, Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit. Int. J. Pediatr. Endocrinol. 2014(1), 15 (2014). https://doi.org/10.1186/1687-9856-2014-15CrossRefPubMedPubMedCentral

10.

V.L. Chulani, L.P. Gordon, Adolescent growth and development. Prim. Care 41(3), 465 (2014). 10.1016/j.pop.2014.05.002–487CrossRef

11.

J.C. Carel, E.A. Eugster, A. Rogol, L. Ghizzoni, M.R. Palmert, E.-L.G.A.C.C. Group, F. Antoniazzi, S. Berenbaum, J.P. Bourguignon, G.P. Chrousos, J. Coste, S. Deal, L. de Vries, C. Foster, S. Heger, J. Holland, K. Jahnukainen, A. Juul, P. Kaplowitz, N. Lahlou, M.M. Lee, P. Lee, D.P. Merke, E.K. Neely, W. Oostdijk, M. Phillip, R.L. Rosenfield, D. Shulman, D. Styne, M. Tauber, J.M. Wit, Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 123(4), e752–e762 (2009). https://doi.org/10.1542/peds.2008-1783CrossRefPubMed

12.

K.C.J. Yuen, S. Llahana, B.S. Miller, Adult growth hormone deficiency: clinical advances and approaches to improve adherence. Expert Rev. Endocrinol. Metab. 14(6), 419–436 (2019). https://doi.org/10.1080/17446651.2019.1689119CrossRefPubMed

13.

J.C. Carel, Management of short stature with GnRH agonist and co-treatment with growth hormone: a controversial issue. Mol. Cell. Endocrinol. 254–255, 226–233 (2006). https://doi.org/10.1016/j.mce.2006.04.034CrossRefPubMed

14.

J. Carel, Can we increase adolescent growth? Eur. J. Endocrinol. 151(Suppl 3), U101-8 (2004). https://doi.org/10.1530/eje.0.151u101CrossRefPubMed

15.

G. Saggese, G. Cesaretti, S. Barsanti, A. Rossi, Combination treatment with growth hormone and gonadotropin-releasing hormone analogs in short normal girls. J. Pediatr. 126(3), 468–473 (1995)CrossRef

16.

A.M. Pasquino, I. Pucarelli, M. Roggini, M. Segni, Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone. J. Clin. Endocrinol. Metab. 85(2), 619–622 (2000). https://doi.org/10.1210/jcem.85.2.6387CrossRefPubMed

17.

J.A. Yanovski, S.R. Rose, G. Municchi, O.H. Pescovitz, S.C. Hill, F.G. Cassorla, G.B. Cutler Jr, Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N. Engl. J. Med. 348(10), 908–917 (2003). https://doi.org/10.1056/NEJMoa013555CrossRefPubMed

18.

L. Dunkel, Treatment of idiopathic short stature: effects of gonadotropin-releasing hormone analogs, aromatase inhibitors and anabolic steroids. Horm. Res. Paediatr. 76(Suppl 3), 27–29 (2011). https://doi.org/10.1159/000330150CrossRefPubMed

19.

R. Balducci, V. Toscano, A. Mangiantini, G. Municchi, F. Vaccaro, S. Picone, A. Di Rito, B. Boscherini, Adult height in short normal adolescent girls treated with gonadotropin-releasing hormone analog and growth hormone. J. Clin. Endocrinol. Metab. 80(12), 3596–3600 (1995). https://doi.org/10.1210/jcem.80.12.8530605CrossRefPubMed

20.

D. Lindner, J.C. Job, J.L. Chaussain, Failure to improve height prediction in short-stature pubertal adolescents by inhibiting puberty with luteinizing hormone-releasing hormone analogue. Eur. J. Pediatr. 152(5), 393–396 (1993)CrossRef

21.

J.C. Carel, F. Hay, R. Coutant, D. Rodrigue, J.L. Chaussain, Gonadotropin-releasing hormone agonist treatment of girls with constitutional short stature and normal pubertal development. J. Clin. Endocrinol. Metab. 81(9), 3318–3322 (1996). https://doi.org/10.1210/jcem.81.9.8784090CrossRefPubMed

22.

C. Bouvattier, J. Coste, D. Rodrigue, C. Teinturier, J.C. Carel, J.L. Chaussain, P.F. Bougneres, Lack of effect of GnRH agonists on final height in girls with advanced puberty: a randomized long-term pilot study. J. Clin. Endocrinol. Metab. 84(10), 3575–3578 (1999). https://doi.org/10.1210/jcem.84.10.6032CrossRefPubMed

23.

R. Lanes, P. Gunczler, Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty. Clin. Endocrinol. 49(2), 197–202 (1998)CrossRef

24.

D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, P. Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535 (2009). https://doi.org/10.1136/bmj.b2535CrossRefPubMedPubMedCentral

25.

J.P. Frindik, J. Baptista, Adult height in growth hormone deficiency: historical perspective and examples from the national cooperative growth study. Pediatrics 104(4 Pt 2), 1000–1004 (1999)CrossRef

26.

O. Ghai, V. Paul, A. Bagga. Essential Pediatrics. 7th ed. (CBS Publishers and Distributors Pvt. Limited, India, 2010)

27.

M.B. Ranke, Towards a consensus on the definition of idiopathic short stature. Horm. Res. 45(Suppl 2), 64–66 (1996). https://doi.org/10.1159/000184851CrossRefPubMed

28.

W.A. Marshall, J.M. Tanner, Variations in the pattern of pubertal changes in boys. Arch. Dis. Child. 45(239), 13–23 (1970). https://doi.org/10.1136/adc.45.239.13CrossRefPubMedPubMedCentral

29.

W.A. Marshall, J.M. Tanner, Variations in pattern of pubertal changes in girls. Arch. Dis. Child. 44(235), 291–303 (1969). https://doi.org/10.1136/adc.44.235.291CrossRefPubMedPubMedCentral

30.

M. Crowther, W. Lim, M.A. Crowther, Systematic review and meta-analysis methodology. Blood 116(17), 3140–3146 (2010). https://doi.org/10.1182/blood-2010-05-280883CrossRefPubMed

31.

K. Slim, E. Nini, D. Forestier, F. Kwiatkowski, Y. Panis, J. Chipponi, Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J. Surg. 73(9), 712–716 (2003)CrossRef

32.

R. DerSimonian, R. Kacker, Random-effects model for meta-analysis of clinical trials: an update. Contemp. Clin. Trials 28(2), 105–114 (2007). https://doi.org/10.1016/j.cct.2006.04.004CrossRefPubMed

33.

J. Bowden, J.F. Tierney, A.J. Copas, S. Burdett, Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med. Res. Methodol. 11, 41 (2011). https://doi.org/10.1186/1471-2288-11-41CrossRefPubMedPubMedCentral

34.

I. Benabbad, M. Rosilio, M. Tauber, E. Paris, A. Paulsen, L. Berggren, H. Patel, J.C. Carel, Phoenix Study, G., Growth hormone in combination with leuprorelin in pubertal children with idiopathic short stature. Endocr. Connect. 7(5), 708–718 (2018). https://doi.org/10.1530/EC-18-0137CrossRefPubMedPubMedCentral

35.

S.A. van Gool, G.A. Kamp, H. Visser-van Balen, D. Mul, J.J. Waelkens, M. Jansen, L. Verhoeven-Wind, H.A. Delemarre-van de Waal, S.M. de Muinck Keizer-Schrama, G. Leusink, J.C. Roos, J.M. Wit, Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty. J. Clin. Endocrinol. Metab. 92(4), 1402–1408 (2007). https://doi.org/10.1210/jc.2006-2272CrossRefPubMed

36.

G.A. Kamp, D. Mul, J.J. Waelkens, M. Jansen, H.A. Delemarre-van de Waal, L. Verhoeven-Wind, M. Frolich, W. Oostdijk, J.M. Wit, A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation. J. Clin. Endocrinol. Metab. 86(7), 2969–2975 (2001). https://doi.org/10.1210/jcem.86.7.7650CrossRefPubMed

37.

J.C. Job, J.E. Toublanc, F. Landier, Growth of short normal children in puberty treated for 3 years with growth hormone alone or in association with gonadotropin-releasing hormone agonist. Horm. Res. 41(5-6), 177–184 (1994). https://doi.org/10.1159/000183889CrossRefPubMed

38.

M.A. Magiakou, D. Manousaki, M. Papadaki, D. Hadjidakis, G. Levidou, M. Vakaki, A. Papaefstathiou, N. Lalioti, C. Kanaka-Gantenbein, G. Piaditis, G.P. Chrousos, C. Dacou-Voutetakis, The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J. Clin. Endocrinol. Metab. 95(1), 109–117 (2010). https://doi.org/10.1210/jc.2009-0793CrossRefPubMed

39.

K.O. Klein, P.A. Lee, Gonadotropin-releasing hormone (GnRHa) therapy for central precocious puberty (CPP): review of nuances in assessment of height, hormonal suppression, psychosocial issues, and weight gain, with patient examples. Pediatr. Endocrinol. Rev. 15(4), 298–312 (2018). https://doi.org/10.17458/per.vol15.2018.kl.GnRHaforCPPCrossRefPubMed

40.

R.H. Willemsen, D. Elleri, R.M. Williams, K.K. Ong, D.B. Dunger, Pros and cons of GnRHa treatment for early puberty in girls. Nat. Rev. Endocrinol. 10(6), 352–363 (2014). https://doi.org/10.1038/nrendo.2014.40CrossRefPubMed

41.

S. Li, X. Wang, Y. Zhao, W. Ji, J. Mao, M. Nie, X. Wu, Combined therapy with GnRH analogue and growth hormone increases adult height in children with short stature and normal pubertal onset. Endocrine 69(3), 615–624 (2020). https://doi.org/10.1007/s12020-020-02375-5CrossRefPubMed

42.

N. Khawaja, H. Owaineh, A. Batieha, O. Frahid, M. El-Khateeb, K.M. Ajlouni, The effect of gonadotropin-releasing hormone analogue on final adult height in children with idiopathic short stature. Med. Princ. Pract. 28(6), 509–516 (2019). https://doi.org/10.1159/000499929CrossRefPubMedPubMedCentral

43.

H. Visser-van Balen, R. Geenen, J. Looij, J. Huisman, J.M. Wit, G. Sinnema, The views of young adults and their parents on hormone treatment for short stature in adolescence. Horm. Res. 69(3), 172–179 (2008). https://doi.org/10.1159/000112591CrossRefPubMed

44.

H. Visser-van Balen, R. Geenen, G.A. Kamp, J. Huisman, J.M. Wit, G. Sinnema, Long-term psychosocial consequences of hormone treatment for short stature. Acta Paediatr. 96(5), 715–719 (2007). https://doi.org/10.1111/j.1651-2227.2007.00235.xCrossRefPubMed

45.

M.R. Munafo, J. Flint, Meta-analysis of genetic association studies. Trends Genet 20(9), 439–444 (2004). https://doi.org/10.1016/j.tig.2004.06.014CrossRefPubMed

Titel: A meta-analysis of combination therapy with gonadotrophin-releasing hormone agonist and growth hormone for children with idiopathic short stature and normal timed puberty
verfasst von: Bo Zhou
Shufang Liu
Jianhong Wang
Ting Zhang
Yuan Yuan
Wenquan Niu
Zhixin Zhang
Lin Wang
Publikationsdatum: 27.01.2022
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2022
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-021-02970-0

Association between metabolic syndrome and clinicopathological features of papillary thyroid cancer

Original Article

“The past is a different country, they do things differently there”: using the SEER data-base to assess prognosis in neuroendocrine tumours

Viewpoint

Irisin alleviates FFA induced β-cell insulin resistance and inflammatory response through activating PI3K/AKT/FOXO1 signaling pathway

Original Article

Plasma aldosterone concentration is associated with white matter lesions in patients with primary aldosteronism

Original Article

Thyroid disorders and cardiovascular manifestations: an update

Review

The characteristics and clinical significance of elevated serum IgG4/IgG levels in patients with Graves’ disease

Original Article

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Schützt das tägliche Glas Milch vor Darmkrebs?

17.01.2025
Kolorektales Karzinom
Nachrichten

Die Milch machts – sie bietet Frauen nach Daten einer großen Ernährungsanalyse den besten Darmkrebsschutz aller Lebensmittel, was am hohen Kalziumgehalt liegen dürfte. Am anderen Ende des Spektrums steht der Alkoholkonsum: Das Glas Wein am Abend ist eher ungünstig.

Vorsicht mit Glukokortikoiden bei Glomerulopathie

16.01.2025
Primäre Glomerulonephritiden
Nachrichten

Auch niedrig dosierte Glukokortikoide zur Behandlung einer primären Glomerulopathie lassen offenbar die Infektionsgefahr steigen. In einer US-Studie hing das Risiko vor allem mit der kombinierten Anwendung von Immunsuppressiva zusammen.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

16.01.2025
Zöliakie
Nachrichten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

15.01.2025
Urothelkarzinom
Nachrichten

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

A meta-analysis of combination therapy with gonadotrophin-releasing hormone agonist and growth hormone for children with idiopathic short stature and normal timed puberty